Free Trial

Purple Biotech (PPBT) Stock Price, News & Analysis

+0.03 (+5.22%)
(As of 06/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
46,204 shs
Average Volume
146,920 shs
Market Capitalization
$15.27 million
P/E Ratio
Dividend Yield
Price Target

Purple Biotech MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
1,387.6% Upside
$9.00 Price Target
Short Interest
1.23% of Shares Sold Short
Dividend Strength
News Sentiment
0.44mentions of Purple Biotech in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.52) to ($0.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.13 out of 5 stars

Medical Sector

438th out of 913 stocks

Pharmaceutical Preparations Industry

205th out of 429 stocks

PPBT stock logo

About Purple Biotech Stock (NASDAQ:PPBT)

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

PPBT Stock Price History

PPBT Stock News Headlines

Purple Biotech Ltd (PPBT)
Purple Biotech Ltd ADR
Purple Biotech Ltd. ADR
Purple Biotech Ltd ADR PPBT
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
See More Headlines
Receive PPBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.36 per share


Free Float
Market Cap
$15.27 million
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Gil Efron CPA (Age 58)
    M.A., Chief Executive Officer
    Comp: $455.44k
  • Dr. Michael Schickler Ph.D. (Age 66)
    Head of Clinical & Regulatory Affairs
    Comp: $264.98k
  • Mr. Lior Fhima CPA (Age 47)
    M.B.A., Chief Financial Officer
  • Mr. Ido Morpurgo B.Sc. (Age 52)
    L.L.M., Vice President of Operations

PPBT Stock Analysis - Frequently Asked Questions

Should I buy or sell Purple Biotech stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Purple Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PPBT shares.
View PPBT analyst ratings
or view top-rated stocks.

What is Purple Biotech's stock price target for 2024?

3 Wall Street analysts have issued twelve-month price targets for Purple Biotech's stock. Their PPBT share price targets range from $8.00 to $10.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 1,387.6% from the stock's current price.
View analysts price targets for PPBT
or view top-rated stocks among Wall Street analysts.

How have PPBT shares performed in 2024?

Purple Biotech's stock was trading at $0.78 on January 1st, 2024. Since then, PPBT shares have decreased by 22.4% and is now trading at $0.6050.
View the best growth stocks for 2024 here

Are investors shorting Purple Biotech?

Purple Biotech saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 309,900 shares, an increase of 20.3% from the May 15th total of 257,600 shares. Based on an average daily volume of 183,200 shares, the days-to-cover ratio is presently 1.7 days.
View Purple Biotech's Short Interest

When is Purple Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 27th 2024.
View our PPBT earnings forecast

How were Purple Biotech's earnings last quarter?

Purple Biotech Ltd (NASDAQ:PPBT) issued its quarterly earnings results on Tuesday, May, 21st. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01.

How do I buy shares of Purple Biotech?

Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PPBT) was last updated on 6/13/2024 by Staff

From Our Partners